No Comments on ECOG 4599 PDF

to paclitaxel/carboplatin, prolongs survival in previously untreated patients with advanced non-small-cell lung cancer: preliminary results from the ECOG Lung Cancer: Secondary Analyses of the ECOG and PointBreak Trials. Eastern Cooperative Oncology Group (E) and PointBreak studies. ECOG demonstrated longer progression-free (PFS) and overall survival ( OS) with the addition of bevacizumab at a dose of 15 mg/m2.

Author: Kajind Nehn
Country: Turkey
Language: English (Spanish)
Genre: History
Published (Last): 15 July 2008
Pages: 170
PDF File Size: 5.65 Mb
ePub File Size: 19.45 Mb
ISBN: 464-2-89834-529-9
Downloads: 69107
Price: Free* [*Free Regsitration Required]
Uploader: Fenrijas

Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer.

There was no difference in OS The optimal dose of bevacizumab also remains unclear, although the ECOG trial using the higher dose was the only trial to show significant improvement in survival. In the initial publication, survival was not reported and increased PFS for the lower-dose arm was demonstrated [ 11 ]. Treating patients with EGFR sensitizing mutations: Should older patients be treated with bevacizumab?

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

They also conclude that bevacizumab showed greater efficacy in patients with adenocarcinoma, and lower body weight loss, but detected no apparent interaction of the treatment effect with age. Weekly paclitaxel, carboplatin, cetuximab, and cetuximab, docetaxel, cisplatin, and fluorouracil, followed by local therapy in previously untreated, locally advanced head and neck squamous cell carcinoma. Karrison; Evidence-based role of bevacizumab in non-small cell lung cancer, Annals of OncologyVolume 24, Issue 1, 1 JanuaryPages 6—9, https: Bevacizumab’s interaction with docetaxel Taxotere or nab-paclitaxel is not well established in lung cancer and will be of interest.

A total of four trials were analyzed including two phase III studies and two randomized phase II trials. The median survival was Comment in N Engl J Med. Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab.

Of interest, only patients with non-squamous cell histology were eligible. A number of other anti-angiogenic agents have been investigated in advanced stage NSCLC without success. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: Analyzed separately, these trials support the administration of bevacizumab with carboplatin and paclitaxel, while its administration with gemcitabine underperforms for the survival end point and is not clinically relevant since gemcitabine is preferentially given to patients with squamous cell histology who are poor candidates for bevacizumab due to risk of pulmonary hemorrhage.


Overall survival with cisplatin—gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: As mentioned above, any clinical interaction with gemcitabine is likely to be small. Exploratory analysis suggested that the doublet maintenance arm might be superior in patients who continued on trial during the maintenance treatment phase, a finding which is consistent with data from other pemetrexed-based maintenance chemotherapy trials [ 2 ].

The principles of anti-angiogenic therapy have been of laboratory and clinical interest for many years [ 6 ]. One of these JO reached statistical significance in favor of the addition of bevacizumab for the PFS end point [ 14 ]. As discussed earlier, the paper is also diminished by the fact that individual patient data were not utilized and updates beyond those of the initial database were not carried out.

Prognostic significance of angiogenesis and angiogenic growth factors in nonsmall cell lung cancer. The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non-small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths.

ECOG will continue to dominate current treatment recommendations and the only evidence-based regimen to which bevacizumab should reasonably be added as a standard remains carboplatin and paclitaxel. Since then it has been established that gemcitabine is inferior to pemetrexed in non-squamous histology [ eog ].

It was originally intended that this summary level analysis would be followed by individual patient data but this aspect of the work unfortunately was not carried out. The median progression-free survival in the two groups was 6. This strategy has been only marginally successful. Randomized phase II study of first-line ecg with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer.

The overall marginally positive statistical survival data reported by the authors are most likely explained by the fact that the large paclitaxel-based trial ECOG is not fundamentally disturbed by the less positive gemcitabine trial AVAiLwhile the two smaller paclitaxel-based studies contribute only marginally to the overall results.


Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Subset analysis suggested that older patients derived no benefit from the addition of bevacizumab [ 10 ]. Sign In or Create an Account.

Maintenance chemotherapy for advanced non-small cell lung cancer: In that case, the doublet would likely be more tolerable and cost-effective. Close mobile search navigation Article navigation.

Of greater clinical interest has been the interaction of pemetrexed with bevacizumab. In this meta-analysis, diminished activity of bevacizumab in older patients was not seen, while the single-trial sub-analysis of ECOG suggested no benefit for older edog.

The primary end point was overall survival. Three of the trials eocg a paclitaxel Taxol -based regimen and one used gemcitabine. However, this ecov not a randomized comparison and therefore, is subject to bias. Paclitaxel—carboplatin alone or with bevacizumab for non-small-cell 44599 cancer. A later survival analysis failed to show a survival benefit for the triplet regimen [ 12 ]. The role of bevacizumab in the maintenance setting remains unclear.

Its precise contribution to increasing survival remains unclear. This meta-analysis seems to suggest possible increased benefits in patients with stage IIIB disease, although it is not clear whether this included patients with stage IIIB disease due to advanced nodal stage or due to pleural effusion. Anti-angiogenic therapy continues to hold promise and clearly benefits some patients.

Both bevacizumab and pemetrexed can be administered as maintenance and it will be crucial to determine if both the drugs together truly outperform the individual drugs in that setting.

The broad conclusion that bevacizumab can be added to doublet chemotherapy with a survival benefit seems exaggerated, given that only two specific doublets were examined, one in patients who would no longer be offered the drug i. Given the associated cost and toxicity however, optimizing the patient-population exposed 45999 these agents remains a high priority.

Does bevacizumab selectively enhance paclitaxel-based regimens?